GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immune Design Corp (NAS:IMDZ) » Definitions » PB Ratio

Immune Design (Immune Design) PB Ratio : 3.07 (As of May. 11, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Immune Design PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-11), Immune Design's share price is $5.85. Immune Design's Book Value per Share for the quarter that ended in Dec. 2018 was $1.91. Hence, Immune Design's PB Ratio of today is 3.07.

The historical rank and industry rank for Immune Design's PB Ratio or its related term are showing as below:

IMDZ's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.5
* Ranked among companies with meaningful PB Ratio only.

Back to Basics: PB Ratio


Immune Design PB Ratio Historical Data

The historical data trend for Immune Design's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immune Design PB Ratio Chart

Immune Design Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
PB Ratio
Get a 7-Day Free Trial 7.83 3.71 1.47 1.35 0.68

Immune Design Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.35 1.23 1.88 1.59 0.68

Competitive Comparison of Immune Design's PB Ratio

For the Biotechnology subindustry, Immune Design's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immune Design's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immune Design's PB Ratio distribution charts can be found below:

* The bar in red indicates where Immune Design's PB Ratio falls into.



Immune Design PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Immune Design's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2018)
=5.85/1.908
=3.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Immune Design  (NAS:IMDZ) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Immune Design PB Ratio Related Terms

Thank you for viewing the detailed overview of Immune Design's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Immune Design (Immune Design) Business Description

Traded in Other Exchanges
N/A
Address
1616 Eastlake Avenue East, Suite 310, Seattle, WA, USA, 98102
Immune Design is a clinical-stage immunotherapy company. Its focus is next-generation in vivo methods intended to enable the body's immune system to fight diseases. The company's therapies have a broad potential approach across multiple therapeutic areas. Nevertheless, the company's target is oncology, and it is developing tumor-specific cytotoxic T cells to fight cancer. The main discoveries are CMB305 and G100, immuno-oncology approaches that are believed to address the shortcomings of existing oncological therapies.
Executives
William R Ringo director
David Baltimore director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Edward Penhoet director ONE EMBARCADERO CENTER SUITE 3700, SAN FRANCISCO CA 94111
Susan L. Kelley director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Carlos V Paya director, officer: President and CEO C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
David V Goeddel 10 percent owner, other: Managing Partner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Peter Svennilson 10 percent owner, other: Managing Partner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tim Kutzkey 10 percent owner, other: Managing Partner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii Gp, Lp 10 percent owner, other: General Partner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Capital, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc 10 percent owner, other: General Partner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Column Group L P 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Gp, Lp 10 percent owner, other: General Partner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005